Cytotect® CP
Protecting precious life - Protection against CMV infection
Cytotect® CP is indicated for prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly transplant recipients.1
The concomitant use of adequate virostatic agents should be considered for CMV prophylaxis.1
Cytotect® CP can be used in patients after both SOT and HSCT.1
® The use of registered trademarks is country specific. Cytotect CP may not be registered in some countries. See local guidelines for licensing details.
References:
1, Cytotect® CP. Summary of Product Characteristics.
Cytotect CP® Biotest – Basic Information
Cytotect CP® Biotest 100 U/ml solution for infusion. Active substance: Human cytomegalovirus immunoglobulin. Composition: Human plasma protein 50 mg/ml (of which at least 96 % is immunoglobulin G), content of antibodies against cytomegalovirus of 100 U*/ml (*Units of the Paul-Ehrlich-Institut reference preparation), IgA content limitation: 2000 mcg/ml, Glycine, water for injections. Therapeutic indications: Prophyl. of clinic. manifest. of CMV-infect. in patients subj. to immunosuppress. therapy , particularly in transplant recipients. Concomitant use of adequate virostatic agents should be considered. Contraindications: Hypersensitivity to the active substance or any of the excipients; pat. with select. IgA deficiency with antibodies to IgA. Undesirable effects: Headache, joint / back pain, chills, dizziness, fever, nausea, vomiting, tiredness, hypersensitivity, allerg. / anaphylact. / anaphylactoid react., anaphylact. shock, sudden fall in blood pressure, low blood pressure, revers. haemolyt react., haemolyt. anaemia, thromboembol. react.(such as myocard. infarct., stroke, pulmon. embolism, deep vein thromboses), revers. asept. meningitis, (trans.) skin react. (such as rash, erythema, drug eruption, pruritus, cutan. lupus erythematosus), serum creatinine level increase, acute renal failure, TRALI.
Biotest Pharma GmbH, Landsteinerstr. 5, 63303 Dreieich
Medical prescription. Information as of June 2019.